Charles River Provides Translational Expertise at Neuroscience 2024

CRL 10.03.2024

Full Press ReleaseSEC FilingsOur CRL Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
  • 01.16.2025 - Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform
  • 01.14.2025 - Charles River Laboratories at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 11.12.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.08.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 3, 2024--Charles River Laboratories International, Inc.(NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 2024, the annual meeting of theSociety for Neuroscience(SfN). The meeting, which brings together leading researchers from across the globe, will take place fromOctober 5-9inChicago, IL.

“Charles River is committed to changing the course of neuroscience research,” saidAntti Nurmi, Ph.D., MSc, General Manager, CNS Pharmacology, Charles River. “We are committed to providing deep translational expertise as a trusted partner for preclinical models, innovative drug discovery, manufacturing, and commercialization, ultimately driving towards better outcomes for our clients and patients.”

Partner with World-Class ScientistsSignificant advances in genetics, pathology, biomarkers, and endpoints are driving momentum in neuroscience drug discovery, from small molecules to advanced therapies. Throughout the conference, Charles River experts will present posters and host discussions on the latest developments in neuroscience research and innovative approaches to tackling neurodegenerative disorders. Highlights include:

  • Establishment and validation of anin vitroco-culture model to study myelination using human iPSC-derived glutamatergic neurons and oligodendrocytes(Presented by Malika Bsibsi:Sunday, October 6, 2024,4:00-5:00 p.m. CDT)
  • An iPSC derived neuroinflammationin vitromodel of neurons and glial cells(Presented by Malika Bsibsi:Monday, October 7, 2024,2:00-3:00 p.m. CDT)

Building Collective MomentumOnMonday, October 7, at10:00 a.m. CDTinProduct Theater2, Charles River’s scientific experts will discuss how significant advances in genetics, pathology, biomarkers, and endpoints within ALS research are impacting drug discovery for this progressive and irreversible neurodegenerative disease.Susanne Back, Ph.D., Senior Manager, CNS Pharmacology andPhilip Mitchell, Ph.D., Director, Integrated Biology, will outline how cellular, and animal models can replicate disease pathology and can be interrogated with translational readouts to support clinical success for small molecules, ASOs, and gene therapies.

Charles River’s global team of nearly 200 neuroscientists work across drug discovery and development, from basic research to regulatory approval, providing the translational science, range of services, and collaborative approach needed to discover novel therapies. Since 2018, Charles River has supported 80 percent of new neuroscience drugs approved by theUnited States Food & Drug Administration(FDA).

Charles River’s end-to-end approach to neurodegenerative disease is evidenced by several recent announcements, including the Company’sstrategic collaboration with CEBINAto advance cutting edge neuroscience research, and theintegration of Insightec’snovel low-frequency ultrasound platform, allowing precise therapeutic delivery of a variety of drugs, including delivery to deep brain structures. Additionally,Logica®, an Artificial Intelligence (AI) powered end-to-end drug discovery solution that translates biological insights into optimized preclinical candidates by leveraging the integration of Valo Health’s AI-powered Opal Computational PlatformTM and Charles River’s leading expertise in drug discovery and preclinical development, recently announced an agreement with H. Lundbeck A/S (Lundbeck),utilizing Logica®to progress critical brain disease research.

A full schedule of Charles River’s activities during Neuroscience 2024 is availableonline. Additionally, expertswill be availableat Booth #417 for meetings with those interested in discussing neuroscience research and drug discovery.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visitwww.criver.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241003547119/en/

Investor:Todd SpencerCorporate Vice President, Investor Relations781-222-6455todd.spencer@crl.com

Media:Amy CianciarusoCorporate Vice President, Public Relations781-222-6168amy.cianciaruso@crl.com

Source:Charles River Laboratories International, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com